<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03919552</url>
  </required_header>
  <id_info>
    <org_study_id>LC2016PY015</org_study_id>
    <nct_id>NCT03919552</nct_id>
  </id_info>
  <brief_title>Cisplatin-based and Carboplatin-based Chemoradiation in Locoregionally Advanced Nasopharyngeal Carcinoma</brief_title>
  <official_title>Intensity-modulated Radiation Therapy Combined With Cisplatin-based or Carboplatin-based Chemotherapy in Locoregionally Advanced Nasopharyngeal Carcinoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Nanfang Hospital of Southern Medical University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Nanfang Hospital of Southern Medical University</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to compare cisplatin-based with carboplatin-based
      chemoradiotherapy in patients with locoregionally advanced nasopharyngeal carcinoma (NPC), in
      order to confirm the value of carboplatin-based chemoradiotherapy in NPC patients.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients presented with non-keratinizing NPC and stage T3-4NxM0/TxN2-3M0 are randomly
      assigned to receive cisplatin-based (control arm) with carboplatin-based (investigational
      arm) chemoradiotherapy. Patients in the investigational arm receive docetaxel (75mg/m2 on day
      1), carboplatin (AUC 4 on day 1) every three weeks for two cycles before the radiotherapy,
      and then receive radical radiotherapy and carboplatin (AUC 5 on day 1) every three weeks for
      three cycles during radiotherapy. Patients in the control arm receive docetaxel (75mg/m2 on
      day 1), cisplatin (75mg/m2 on day 1) every three weeks for two cycles before the
      radiotherapy, and then receive radical radiotherapy and cisplatin (100mg/m2 on day 1) every
      three weeks for three cycles during radiotherapy. Patients are stratified according to stage.
      The primary end point is overall survival (OS). Secondary end points include failure-free
      survival (FFS), distant failure-free survival (D-FFS), locoregional failure-free survival
      (LR-FFS), initial response rates after treatments and toxic effects. All efficacy analyses
      are conducted in the intention-to-treat population; the safety population include only
      patients who receive their randomly assigned treatment.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">January 31, 2018</start_date>
  <completion_date type="Anticipated">June 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">January 31, 2023</primary_completion_date>
  <phase>Phase 3</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Failure-free survival</measure>
    <time_frame>3-year</time_frame>
    <description>Failure-free survival is calculated from the date of randomisation to the date of treatment failure or death from any cause, whichever is first.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Locoregional failure-free survival</measure>
    <time_frame>3-year</time_frame>
    <description>Locoregional failure-free survival is calculated from randomisation to the first locoregional failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Distant failure-free survival</measure>
    <time_frame>3-year</time_frame>
    <description>Distant failure-free survival is calculated from randomisation to the first locoregional failure.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The initial response rates after treatments</measure>
    <time_frame>A week after completion of the last cycle of induction chemotherapy and 16 weeks after completion of radiotherapy.</time_frame>
    <description>The initial response rates is calculated at the time 1 week after completion of the last cycle of induction chemotherapy and 16 weeks after completion of radiotherapy.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Toxic effects</measure>
    <time_frame>3-year</time_frame>
    <description>Radiation and chemotherapy related toxic effects as assessed by CTCAE v4.0.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Overall survival</measure>
    <time_frame>3-year</time_frame>
    <description>Overall survival is calculated from randomization to death from any cause.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">482</enrollment>
  <condition>Cisplatin</condition>
  <condition>Carboplatin</condition>
  <condition>NPC</condition>
  <arm_group>
    <arm_group_label>Carboplatin</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Patients receive docetaxel (75mg/m2 on day 1), carboplatin (AUC 4 on day 1) every three weeks for two cycles before the radiotherapy, and then receive radical radiotherapy and carboplatin (AUC 5 on day 1) every three weeks for three cycles during radiotherapy.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Cisplatin</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Patients receive docetaxel (75mg/m2 on day 1), cisplatin (75mg/m2 on day 1) every three weeks for two cycles before the radiotherapy, and then receive radical radiotherapy and cisplatin (100mg/m2 on day 1) every three weeks for three cycles during radiotherapy.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel,Carboplatin</intervention_name>
    <description>Patients receive docetaxel (75mg/m2 on day 1), carboplatin (AUC 4 on day 1) every three weeks for two cycles before the radiotherapy.</description>
    <arm_group_label>Carboplatin</arm_group_label>
    <other_name>TC induction chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Docetaxel,Cisplatin</intervention_name>
    <description>Patients receive docetaxel (75mg/m2 on day 1), cisplatin (75mg/m2 on day 1) every three weeks for two cycles before the radiotherapy.</description>
    <arm_group_label>Cisplatin</arm_group_label>
    <other_name>TP induction chemotherapy</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Carboplatin-based concurrent chemoradiotherapy</intervention_name>
    <description>Patients receive radical radiotherapy and carboplatin (AUC 5) every three weeks for three cycles during radiotherapy.</description>
    <arm_group_label>Carboplatin</arm_group_label>
    <other_name>Radical radiotherapy and concurrent carboplatin</other_name>
  </intervention>
  <intervention>
    <intervention_type>Radiation</intervention_type>
    <intervention_name>Cisplatin-based concurrent chemoradiotherapy</intervention_name>
    <description>Patients receive radical radiotherapy and cisplatin (100mg/m2) every three weeks for three cycles during radiotherapy.</description>
    <arm_group_label>Cisplatin</arm_group_label>
    <other_name>Radical radiotherapy and concurrent cisplatin</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients with newly histologically confirmed non-keratinizing (according to World
             Health Organization (WHO) histologically type).

          -  Tumor staged as T3-4Nx/TxN2-3 (according to the 8th American Joint Commission on
             Cancer edition).

          -  No evidence of distant metastasis (M0).

          -  Satisfactory performance status: Karnofsky scale (KPS) &gt; 70.

          -  Adequate marrow: leucocyte count ≥4000/μL, hemoglobin ≥90g/L and platelet count
             ≥100000/μL.

          -  Normal liver function test: Alanine Aminotransferase (ALT)、Aspartate Aminotransferase
             (AST) &lt;1.5×upper limit of normal (ULN) concomitant with alkaline phosphatase (ALP)
             ≤2.5×ULN, and bilirubin ≤ULN.

          -  Adequate renal function: creatinine clearance ≥60 ml/min.

          -  Patients must be informed of the investigational nature of this study and give written
             informed consent.

        Exclusion Criteria:

          -  WHO Type keratinizing squamous cell carcinoma or basaloid squamous cell carcinoma.

          -  Age ≥65 years or &lt;18 years.

          -  Treatment with palliative intent.

          -  Prior malignancy except adequately treated basal cell or squamous cell skin cancer, in
             situ cervical cancer.

          -  Pregnancy or lactation.

          -  History of previous radiotherapy (except for non-melanomatous skin cancers outside
             intended RT treatment volume).

          -  Prior chemotherapy or surgery (except diagnostic) to primary tumor or nodes.

          -  Any severe intercurrent disease, which may bring unacceptable risk or affect the
             compliance of the trial, for example, unstable cardiac disease requiring treatment,
             renal disease, chronic hepatitis, diabetes with poor control (fasting plasma glucose
             &gt;1.5×ULN), and emotional disturbance.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>64 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jian Guan</last_name>
    <role>Study Chair</role>
    <affiliation>Nanfang Hospital of Southern Medical University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jian Guan, Ph.D.</last_name>
    <phone>+86-13632102247</phone>
    <email>51643930@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Southern medical university</name>
      <address>
        <city>Guangzhou</city>
        <state>Guangdong</state>
        <zip>510515</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jian Guan, M.D.</last_name>
      <phone>86+13632102247</phone>
      <email>guanjian5461@163.com</email>
    </contact>
    <investigator>
      <last_name>Jian Guan, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <reference>
    <citation>Haddad RI, Shin DM. Recent advances in head and neck cancer. N Engl J Med. 2008 Sep 11;359(11):1143-54. doi: 10.1056/NEJMra0707975.</citation>
    <PMID>18784104</PMID>
  </reference>
  <reference>
    <citation>Guan J, Zhang Y, Li Q, Zhang Y, Li L, Chen M, Xiao N, Chen L. A meta-analysis of weekly cisplatin versus three weekly cisplatin chemotherapy plus concurrent radiotherapy (CRT) for advanced head and neck cancer (HNC). Oncotarget. 2016 Oct 25;7(43):70185-70193. doi: 10.18632/oncotarget.11824.</citation>
    <PMID>27602493</PMID>
  </reference>
  <reference>
    <citation>Hashibe M, Brennan P, Chuang SC, Boccia S, Castellsague X, Chen C, Curado MP, Dal Maso L, Daudt AW, Fabianova E, Fernandez L, Wünsch-Filho V, Franceschi S, Hayes RB, Herrero R, Kelsey K, Koifman S, La Vecchia C, Lazarus P, Levi F, Lence JJ, Mates D, Matos E, Menezes A, McClean MD, Muscat J, Eluf-Neto J, Olshan AF, Purdue M, Rudnai P, Schwartz SM, Smith E, Sturgis EM, Szeszenia-Dabrowska N, Talamini R, Wei Q, Winn DM, Shangina O, Pilarska A, Zhang ZF, Ferro G, Berthiller J, Boffetta P. Interaction between tobacco and alcohol use and the risk of head and neck cancer: pooled analysis in the International Head and Neck Cancer Epidemiology Consortium. Cancer Epidemiol Biomarkers Prev. 2009 Feb;18(2):541-50. doi: 10.1158/1055-9965.EPI-08-0347. Epub 2009 Feb 3.</citation>
    <PMID>19190158</PMID>
  </reference>
  <reference>
    <citation>Blot WJ, McLaughlin JK, Winn DM, Austin DF, Greenberg RS, Preston-Martin S, Bernstein L, Schoenberg JB, Stemhagen A, Fraumeni JF Jr. Smoking and drinking in relation to oral and pharyngeal cancer. Cancer Res. 1988 Jun 1;48(11):3282-7.</citation>
    <PMID>3365707</PMID>
  </reference>
  <reference>
    <citation>Chang ET, Adami HO. The enigmatic epidemiology of nasopharyngeal carcinoma. Cancer Epidemiol Biomarkers Prev. 2006 Oct;15(10):1765-77. Review.</citation>
    <PMID>17035381</PMID>
  </reference>
  <reference>
    <citation>Klein G. Nasopharyngeal carcinoma (NPC) is an enigmatic tumor. Semin Cancer Biol. 2002 Dec;12(6):415-8.</citation>
    <PMID>12450726</PMID>
  </reference>
  <reference>
    <citation>Buell P. The effect of migration on the risk of nasopharyngeal cancer among Chinese. Cancer Res. 1974 May;34(5):1189-91.</citation>
    <PMID>4842361</PMID>
  </reference>
  <reference>
    <citation>Ozer E, Grecula JC, Agrawal A, Rhoades CA, Young DC, Schuller DE. Long-term results of a multimodal intensification regimen for previously untreated advanced resectable squamous cell cancer of the oral cavity, oropharynx, or hypopharynx. Laryngoscope. 2006 Apr;116(4):607-12.</citation>
    <PMID>16585867</PMID>
  </reference>
  <reference>
    <citation>Fallai C, Bolner A, Signor M, Gava A, Franchin G, Ponticelli P, Taino R, Rossi F, Ardizzoia A, Oggionni M, Crispino S, Olmi P. Long-term results of conventional radiotherapy versus accelerated hyperfractionated radiotherapy versus concomitant radiotherapy and chemotherapy in locoregionally advanced carcinoma of the oropharynx. Tumori. 2006 Jan-Feb;92(1):41-54.</citation>
    <PMID>16683383</PMID>
  </reference>
  <reference>
    <citation>Blanchard P, Baujat B, Holostenco V, Bourredjem A, Baey C, Bourhis J, Pignon JP; MACH-CH Collaborative group. Meta-analysis of chemotherapy in head and neck cancer (MACH-NC): a comprehensive analysis by tumour site. Radiother Oncol. 2011 Jul;100(1):33-40. doi: 10.1016/j.radonc.2011.05.036. Epub 2011 Jun 16.</citation>
    <PMID>21684027</PMID>
  </reference>
  <reference>
    <citation>Sun Y, Li WF, Chen NY, Zhang N, Hu GQ, Xie FY, Sun Y, Chen XZ, Li JG, Zhu XD, Hu CS, Xu XY, Chen YY, Hu WH, Guo L, Mo HY, Chen L, Mao YP, Sun R, Ai P, Liang SB, Long GX, Zheng BM, Feng XL, Gong XC, Li L, Shen CY, Xu JY, Guo Y, Chen YM, Zhang F, Lin L, Tang LL, Liu MZ, Ma J. Induction chemotherapy plus concurrent chemoradiotherapy versus concurrent chemoradiotherapy alone in locoregionally advanced nasopharyngeal carcinoma: a phase 3, multicentre, randomised controlled trial. Lancet Oncol. 2016 Nov;17(11):1509-1520. doi: 10.1016/S1470-2045(16)30410-7. Epub 2016 Sep 27.</citation>
    <PMID>27686945</PMID>
  </reference>
  <reference>
    <citation>Blanchard P, Lee A, Marguet S, Leclercq J, Ng WT, Ma J, Chan AT, Huang PY, Benhamou E, Zhu G, Chua DT, Chen Y, Mai HQ, Kwong DL, Cheah SL, Moon J, Tung Y, Chi KH, Fountzilas G, Zhang L, Hui EP, Lu TX, Bourhis J, Pignon JP; MAC-NPC Collaborative Group. Chemotherapy and radiotherapy in nasopharyngeal carcinoma: an update of the MAC-NPC meta-analysis. Lancet Oncol. 2015 Jun;16(6):645-55. doi: 10.1016/S1470-2045(15)70126-9. Epub 2015 May 6.</citation>
    <PMID>25957714</PMID>
  </reference>
  <reference>
    <citation>Munro AJ. An overview of randomised controlled trials of adjuvant chemotherapy in head and neck cancer. Br J Cancer. 1995 Jan;71(1):83-91.</citation>
    <PMID>7819055</PMID>
  </reference>
  <reference>
    <citation>Akhlaghi F, Esmaeelinejad M, Shams A, Augend A. Evaluation of neo-adjuvant, concurrent and adjuvant chemotherapy in the treatment of head and neck squamous cell carcinoma: a meta-analysis. J Dent (Tehran). 2014 May;11(3):290-301. Epub 2014 May 31.</citation>
    <PMID>25628664</PMID>
  </reference>
  <verification_date>April 2019</verification_date>
  <study_first_submitted>April 25, 2018</study_first_submitted>
  <study_first_submitted_qc>April 14, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 18, 2019</study_first_posted>
  <last_update_submitted>April 14, 2019</last_update_submitted>
  <last_update_submitted_qc>April 14, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 18, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Nasopharyngeal Carcinoma</keyword>
  <keyword>cisplatin</keyword>
  <keyword>carboplatin</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Carcinoma</mesh_term>
    <mesh_term>Nasopharyngeal Carcinoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cisplatin</mesh_term>
    <mesh_term>Carboplatin</mesh_term>
    <mesh_term>Docetaxel</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

